Qomolangma Acquisition Corp.

$ Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000101376224001078 Filed on July 25, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023 Q1

Balance Sheet

Concept	2024 Q1	2023 Q4	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.310K	$9.220K	$170.0K
YoY Change	-96.29%	-95.39%	70.0%
Cash & Equivalents	$6.309K	$9.222K	$167.8K
Short-Term Investments
Other Short-Term Assets	$34.89K	$69.78K	$230.0K
YoY Change	-84.83%	-70.93%
Inventory
Prepaid Expenses	$34.89K	$69.78K	$233.3K
Receivables
Other Receivables
Total Short-Term Assets	$41.20K	$79.00K	$401.1K
YoY Change	-89.73%	-81.71%	301.07%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$9.441M	$9.299M	$54.49M
YoY Change	-82.67%	-82.77%
Other Assets
YoY Change
Total Long-Term Assets	$9.441M	$9.299M	$54.49M
YoY Change	-82.67%	-82.77%	36223.76%
TOTAL ASSETS
Total Short-Term Assets	$41.20K	$79.00K	$401.1K
Total Long-Term Assets	$9.441M	$9.299M	$54.49M
Total Assets	$9.482M	$9.378M	$54.89M
YoY Change	-82.72%	-82.76%	21854.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$841.5K
YoY Change
Accrued Expenses	$208.9K	$829.9K	$560.0K
YoY Change	-62.7%	566.08%	1300.01%
Deferred Revenue
YoY Change
Short-Term Debt	$937.3K	$937.3K	$360.0K
YoY Change	160.35%	485.78%	80.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.023M	$2.909M	$1.084M
YoY Change	178.82%	683.8%	351.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.109M	$2.109M	$2.110M
YoY Change	-0.04%	-0.04%
Total Long-Term Liabilities	$2.109M	$2.109M	$2.110M
YoY Change	-0.04%	-0.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.023M	$2.909M	$1.084M
Total Long-Term Liabilities	$2.109M	$2.109M	$2.110M
Total Liabilities	$5.141M	$5.034M	$3.237M
YoY Change	58.82%	100.04%	1248.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.598M	-$4.483M	-$93.26K
YoY Change	4830.04%	-3524.62%
Common Stock	$166.00	$166.00	$166.00
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.597M	-$4.483M	$1.019M
YoY Change
Total Liabilities & Shareholders Equity	$9.482M	$9.378M	$54.89M
YoY Change	-82.72%	-82.76%	21854.68%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023 Q1

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-41518
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	Qomolangma Acquisition Corp.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3733656
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1178 Broadway
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	3rd Floor
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10010
CY2024Q1	dei	City Area Code CityAreaCode	(646)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	791-7587
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	true
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2500480	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6309	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9222	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	34891	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	69781	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	41200	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	79003	usd
CY2024Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	9440722	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	9299336	usd
CY2024Q1	us-gaap	Assets Assets	9481922	usd
CY2023Q4	us-gaap	Assets Assets	9378339	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	841491	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	829931	usd
CY2024Q1	qomo	Franchise Tax Payable FranchiseTaxPayable	30500	usd
CY2023Q4	qomo	Franchise Tax Payable FranchiseTaxPayable	24400	usd
CY2024Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	465475	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	434300	usd
CY2024Q1	qomo	Exercise Tax Liabilies ExerciseTaxLiabilies	469218	usd
CY2023Q4	qomo	Exercise Tax Liabilies ExerciseTaxLiabilies	469218	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3022817	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2909214	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	8719	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	15684	usd
CY2024Q1	qomo	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	2109200	usd
CY2023Q4	qomo	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	2109200	usd
CY2024Q1	us-gaap	Liabilities Liabilities	5140736	usd
CY2023Q4	us-gaap	Liabilities Liabilities	5034098	usd
CY2024Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	16000000	shares
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	16000000	shares
CY2024Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	837857	shares
CY2024Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	837857	shares
CY2024Q1	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.67
CY2023Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.54
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	8938530	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	8827454	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1662623	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1662623	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1662623	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1662623	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	166	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	166	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4597510	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4483379	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-4597344	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4483213	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9481922	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9378339	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	94131	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	666320	usd
CY2024Q1	qomo	Franchise Tax Expense FranchiseTaxExpense	6100	usd
CY2023Q1	qomo	Franchise Tax Expense FranchiseTaxExpense	12700	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-100231	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-679020	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	121386	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	572382	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	21155	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-106638	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24210	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	117533	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3055	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-224171	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4483213	usd
CY2024Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	111076	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3055	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-4597344	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5045303	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	3802141	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-224171	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1018991	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3055	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-224171	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	121386	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	572382	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6965	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	7232	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-34890	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2180	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	26328	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	435406	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	30000	usd
CY2024Q1	qomo	Increase Decrease In Franchise Tax Payable IncreaseDecreaseInFranchiseTaxPayable	6100	usd
CY2023Q1	qomo	Increase Decrease In Franchise Tax Payable IncreaseDecreaseInFranchiseTaxPayable	-32728	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	31175	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	110301	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2913	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-274162	usd
CY2023Q1	qomo	Proceeds From Cash Withdrawal From Trust Account To Pay Franchise Tax ProceedsFromCashWithdrawalFromTrustAccountToPayFranchiseTax	45429	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	45429	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	200000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	200000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2913	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-28733	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9222	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	196510	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6309	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167777	usd
CY2024Q1	qomo	Extension Fees Paid By The Sponsor Through Due To Related Party ExtensionFeesPaidByTheSponsorThroughDueToRelatedParty	20000	usd
CY2024Q1	qomo	Accrued Expenses Paid By The Sponsor Through Due To Related Party AccruedExpensesPaidByTheSponsorThroughDueToRelatedParty	14768	usd
CY2024Q1	qomo	Accretionof Common Stockto Redemption Value AccretionofCommonStocktoRedemptionValue	111076	usd
CY2023Q1	qomo	Accretionof Common Stockto Redemption Value AccretionofCommonStocktoRedemptionValue	3802141	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 — Description of Organization and Business Operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Qomolangma Acquisition Corp. (the “Company”) is a blank check company incorporated as a Delaware corporation on May 6, 2021. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (“Business Combination”). The Company intends to pursue target businesses that are strategically significant in the Asian markets and focus on businesses with a total enterprise value of between $300,000,000 and $500,000,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024, the Company had not commenced any operations. All activities through March 31, 2024 are related to the Company’s formation and the proposed initial public offering (“IPO” as defined below) and, subsequent to the IPO, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s sponsor is Qomolangma Investments LLC (the “Sponsor”), a Delaware limited liability company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration statement for the Company’s IPO became effective on September 29, 2022. On October 4, 2022, the Company consummated the IPO of 5,000,000 units at an offering price of $10.00 per unit (the “Public Units’), generating gross proceeds of $50,000,000. Simultaneously with the closing of the IPO, the Company sold to the Sponsor, in a private placement, 260,500 units, at $10.00 per unit (the “Private Units”), generating total gross proceeds of $2,605,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transaction costs from the IPO amounted to $4,222,030, consisting of $875,000 of underwriting fees, $2,000,000 of deferred underwriting fees (payable only upon completion of a Business Combination) and $1,347,030 of other offering costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company granted the underwriter a 45-day option to purchase up to 750,000 additional Public Units to cover over-allotments, if any. On October 4, 2022, the underwriter partially exercised the over-allotment option and purchased 273,000 Public Units at a price of $10.00 per Public Unit on October 7, 2022, generating gross proceeds of $2,730,000. Simultaneously with the closing of the over-allotment option, the Company consummated the private placement of an additional 8,873 Private Units generating gross proceeds of $88,725.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A total of $53,520,950 ($10.15 per Unit) of the net proceeds from the sale of Units in the IPO (including the Over-Allotment Option Units) and the private placements on October 4, 2022 and October 7, 2022, was placed in a trust account (the “Trust Account”) maintained by American Stock Transfer & Trust Company as a trustee and are invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended (the “Investment Company Act”), and that invest only in direct U.S. government treasury obligations. These funds will not be released until the earlier of the completion of the initial Business Combination and the liquidation due to the Company’s failure to complete a Business Combination within the applicable period of time. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public stockholders. In addition, interest income earned on investments held in the Trust Account may be released to the Company to pay its income or other tax obligations. With these exceptions, expenses incurred by the Company may be paid prior to a Business Combination only from the net proceeds of the IPO and private placement not held in the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Nasdaq listing rules, the Company’s initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80% of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be required to satisfy the 80% test. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will provide its holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.15 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income tax obligations).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares of common stock voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the Company’s Sponsor and any of the Company’s officers or directors that may hold Founder Shares (as defined in Note 5) (the “Initial Stockholders”) and the underwriters have agreed (a) to vote their Founder Shares, Private Shares (as defined in Note 4), and any Public Shares purchased during or after the IPO in favor of approving a Business Combination and (b) not to convert any shares (including the Founder Shares) in connection with a stockholder vote to approve, or sell the shares to the Company in any tender offer in connection with, a proposed Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Initial Stockholders have agreed (a) to waive their redemption rights with respect to the Founder Shares, Private Shares, and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose, or vote in favor of, an amendment to the Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Initially, the Company had until July 4, 2023 (or up to July 4, 2024 if the time to complete a business combination is extended as described herein) to consummate a Business Combination. In addition, if the Company anticipated that it would not be able to consummate a Business Combination within 9 months, the Company was able to extend the period of time to consummate a Business Combination up to twelve times, each by an additional one month (for a total of 21 months to complete a Business Combination). In order to extend the time available for the Company to consummate a Business Combination, the Company’s insiders or their affiliates or designees, upon five days’ advance notice prior to the applicable deadline, was required to deposit into the Trust Account $174,009 ($0.033 per Public Share per month), on or prior to the date of the applicable deadline, for each extension.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 29, 2023, the Company held a special meeting of stockholders (the “June Special Meeting”). At the June Special Meeting, the stockholders amended the Company’s Amended and Restated Certificate of Incorporation to allow the Company to consummate a business combination until August 4, 2023 (or up to August 4, 2024 if the time to complete a business combination is extended as described herein) to consummate a Business Combination. In addition, if the Company anticipates that it may not be able to consummate a Business Combination by August 4, 2023, the Company may extend the period of time to consummate a Business Combination up to twelve times, each by an additional one month (for a total of 22 months to complete a Business Combination) (the “Combination Period”). In order to extend the time available for the Company to consummate a Business Combination, the Company’s insiders or their affiliates or designees, upon five days’ advance notice prior to the applicable deadline, must deposit into the Trust Account the lesser of $0.033 per outstanding share and $80,000 per month, on or prior to the date of the applicable deadline, for each extension.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the June Special Meeting, an aggregate of 2,126,934 shares with redemption value of approximately $22,141,383 (or $10.41 per share) of the Company’s common stock were tendered for redemption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 29, 2023, the Sponsor made a deposit of $240,000 to the Trust Account and extended the period of time the Company has to consummate an initial Business Combination from July 4, 2023 to October 4, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2023, the Company held a special meeting of stockholders (the “September Special Meeting”). At the Special Meeting, the stockholders amended the Company’s Amended and Restated Certificate of Incorporation to allow the Company to undertake an initial business combination with an entity or business, with a physical presence, operation, or other significant ties to China (a “China-based Target”) or which may subject the post-business combination business to the laws, regulations and policies of China (including Hong Kong and Macao), or entity or business that conducts operations in China through variable interest entities, or VIEs, pursuant to a series of contractual arrangements with the VIE and its shareholders on one side, and a China-based subsidiary of the China-based Target, on the other side.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the September Special Meeting, an aggregate of 1,233,054 shares with redemption value of approximately $13,082,703 (or $10.61 per share) of the Company’s common stock were tendered for redemption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 31, 2023 and November 29, 2023, the Sponsor made a deposit of $63,129 each time into the Trust Account and extended the period of time the Company has to consummate an initial Business Combination from November 4, 2023 to January 4, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 7, 2023, the Company held a special meeting of stockholders. At the special meeting, holders of 3,575,635 shares of common stock of the Company were present in person or by proxy, representing 81.18% of the total shares of common stock as of November 15, 2023, the record date for the special meeting, and constituting a quorum for the transaction of business. At the special meeting, the stockholders approved further amendments to our amended and restated certificate of incorporation and Trust Agreement to reduce the amount the Company must deposit into the Trust Account to extend the date on which the trustee must liquidate the trust account established by the Company in connection with the IPO to the lesser of $0.033 per outstanding share and $20,000 for each one-month extension.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 29, 2023, the Sponsor made a deposit of $63,129 (which did not reflect a reduction of $38,043 extension fee as a result of the Company’s December 2023 public shares redemption) into the Trust Account and extended the period of time the Company has to consummate an initial Business Combination from December 4, 2023 to January 4, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor made a monthly deposit of $20,000 into the Trust Account from December 2023 to July 2024 and extended the period of time the Company has to consummate an initial Business Combination from January 4, 2024 to August 4, 2024. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (which interest shall be net of taxes payable, and less certain amount of interest to pay dissolution expenses) divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Initial Stockholders have agreed to waive their liquidation rights with respect to the Founder Shares and Private Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor or underwriters acquires Public Shares in or after the IPO, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than $10.15.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below $10.15 per Public Share, except as to any claims by a third party who executed a valid and enforceable agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity, Capital Resources and Going Concern</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024, the Company had $6,309 of cash held outside its trust account and a working capital deficit of $2,981,617. On March 22, 2023, June 26, 2023, September 12, 2023, September 26, 2023 and October 26, 2023, the Sponsor loaned the Company $200,000, $240,000, $150,000, $47,227, and $145,000, respectively, to be used, in part, for extension deposits. All promissory notes bear no interest and are repayable in full upon the consummation of the Company’s Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Sponsor’s deposit of $63,129 each time to the Trust Account on October 31, 2023 and November 29, 2023 (which did not reflect a reduction of $38,043 extension fee as a result of the Company’s December 2023 public shares redemption), and the monthly deposit of $20,000 into the Trust Account from December 2023 to July 2024, the Company has until August 4, 2024 (unless the Company extends the time to complete a Business Combination) to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to continue to incur significant professional costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of a Business Combination. The Company may need to obtain additional financing either to complete its Business Combination or because it becomes obligated to redeem a significant number of public shares upon consummation of its Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is unable to complete its Business Combination because it does not have sufficient funds available, it will be forced to cease operations and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, the Company may need to obtain additional financing in order to meet its obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, management has determined that the liquidity and mandatory liquidation conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, if the Company is unable to complete a Business Combination within the Combination Period, the Company’s board of directors would proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period. As a result, management has determined that such additional condition also raise substantial doubt about the Company’s ability to continue as a going concern. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2022, an armed conflict escalated between Russia and Ukraine. The sanctions announced by the United States and other countries against Russia and Belarus following Russia’s invasion of Ukraine to date include restrictions on selling or importing goods, services, or technology in or from affected regions and travel bans and asset freezes impacting connected individuals and political, military, business, and financial organizations in Russia and Belarus. The United States and other countries could impose wider sanctions and take other actions should the conflict further escalate. Separately, in October 2023, Israel and certain Iranian-backed Palestinian forces began an armed conflict in Israel, the Gaza Strip, and surrounding areas, which threatens to spread to other Middle Eastern countries including Lebanon and Iran. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the ongoing Russia/Ukraine, Hamas/Israel conflicts and/or other future global conflicts, the Company’s ability to consummate a Business Combination, or the operations of a target business with which the Company ultimately consummates a Business Combination, may be materially and adversely affected. In addition, the Company’s ability to consummate a transaction may be dependent on the ability to raise equity and debt financing which may be impacted by these events, including as a result of increased market volatility, or decreased market liquidity in third-party financing being unavailable on terms acceptable to the Company or at all. The impact of this action and potential future sanctions on the world economy and the specific impact on the Company’s financial position, results of operations or ability to consummate a Business Combination are not yet determinable. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Inflation Reduction Act of 2022</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax. The IR Act applies only to repurchases that occur after December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company’s ability to complete a Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the redemptions by the public stockholders in June 2023, September 2023, and December 2023, the Company recorded total excise tax liability of $469,218 as of March 31, 2024. The Company will continue to monitor for updates to the Company’s business along with guidance issued with respect to the IR Act to determine whether any adjustments are needed to the Company’s tax provision in future periods.</p>
CY2022Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	50000000	usd
CY2024Q1	qomo	Transaction Cost TransactionCost	4222030	usd
CY2024Q1	qomo	Underwriting Fees UnderwritingFees	875000	usd
CY2024Q1	qomo	Deferred Underwriting Fees DeferredUnderwritingFees	2000000	usd
CY2024Q1	qomo	Offering Cost OfferingCost	1347030	usd
CY2024Q1	qomo	Maturity Days MaturityDays	P185D
CY2024Q1	qomo	Trust Account Description TrustAccountDescription	Pursuant to Nasdaq listing rules, the Company’s initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80% of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be required to satisfy the 80% test.
CY2024Q1	qomo	Financing Receivable Non Accrual To Outstanding Percent FinancingReceivableNonAccrualToOutstandingPercent	0.50	pure
CY2024Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.15
CY2024Q1	qomo	Minimum Net Tangible Assets Upon Consummation Of Business Combination MinimumNetTangibleAssetsUponConsummationOfBusinessCombination	5000001	usd
CY2024Q1	qomo	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2024Q1	qomo	Deposit Into Trust Account DepositIntoTrustAccount	174009	usd
CY2024Q1	qomo	Public Price Per Share Per Month PublicPricePerSharePerMonth	0.033
CY2024Q1	qomo	Aggregate Shares AggregateShares	1233054	shares
CY2024Q1	qomo	Redemption Value RedemptionValue	13082703	usd
CY2023Q4	qomo	Common Stock Other Shares CommonStockOtherShares	3575635	shares
CY2023Q4	qomo	Percentage Of Common Stock Other Shares PercentageOfCommonStockOtherShares	0.8118	pure
CY2023Q4	us-gaap	Investment Company Issuance Of Shares Per Share InvestmentCompanyIssuanceOfSharesPerShare	0.033
CY2023Q4	qomo	Deposit Into Trust Account DepositIntoTrustAccount	20000	usd
CY2023Q4	us-gaap	Deposits Deposits	63129	usd
CY2023Q4	us-gaap	Payments For Fees PaymentsForFees	38043	usd
CY2024Q1	us-gaap	Net Asset Value Per Share NetAssetValuePerShare	10.15
CY2024Q1	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	10.15
CY2024Q1	us-gaap	Cash Available For Distributions CashAvailableForDistributions	6309	usd
CY2024Q1	qomo	Working Capital WorkingCapital	2981617	usd
CY2023Q1	us-gaap	Loans Payable LoansPayable	200000	usd
CY2023Q2	us-gaap	Loans Payable LoansPayable	240000	usd
CY2023Q3	us-gaap	Loans Payable LoansPayable	150000	usd
CY2023Q3	us-gaap	Loans Payable LoansPayable	47227	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	145000	usd
CY2024Q1	us-gaap	Payments For Fees PaymentsForFees	38043	usd
CY2022Q3	qomo	Effective Income Tax Rate Reconciliation At Federal Excise Tax Percentage EffectiveIncomeTaxRateReconciliationAtFederalExciseTaxPercentage	0.01	pure
CY2022Q3	qomo	Excise Tax Percentage ExciseTaxPercentage	0.01	pure
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these unaudited financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q1	us-gaap	Cash Cash	6309	usd
CY2023Q4	us-gaap	Cash Cash	9222	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.1444	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.1022	pure
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5542373	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5542373	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3055	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-224171	usd
CY2024Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	111076	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	3802141	usd
CY2024Q1	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	-114131	usd
CY2023Q1	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	-4026312	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of March 31, 2024 and December 31, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2024Q1	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2024Q1	us-gaap	Redeemable Noncontrolling Interest Equity Common Redemption Value RedeemableNoncontrollingInterestEquityCommonRedemptionValue	111076	usd
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Redemption Value RedeemableNoncontrollingInterestEquityCommonRedemptionValue	8920393	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	52730000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3532910	usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1845550	usd
CY2022	qomo	Allocation Of Offering Costs Related To Redeemable Shares AllocationOfOfferingCostsRelatedToRedeemableShares	-3932347	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	3409640	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	46828833	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	8920393	usd
CY2023	qomo	Temporary Equity Redemptionof Public Stockholders TemporaryEquityRedemptionofPublicStockholders	-46921772	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	8827454	usd
CY2024Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	111076	usd
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	8938530	usd
CY2024Q1	qomo	Initial Public Offering Expiration InitialPublicOfferingExpiration	P5Y
CY2024Q1	qomo	Public Shares Sold PublicSharesSold	5273000	shares
CY2022Q4	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	119250	shares
CY2022Q4	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	1318250	shares
CY2024Q1	qomo	Founder Shares Percentage FounderSharesPercentage	0.50	pure
CY2022Q4	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	155025	usd
CY2023Q1	us-gaap	Loans Payable LoansPayable	200000	usd
CY2023Q2	us-gaap	Loans Payable LoansPayable	240000	usd
CY2023Q3	us-gaap	Loans Payable LoansPayable	150000	usd
CY2023Q3	us-gaap	Loans Payable LoansPayable	47227	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	145000	usd
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	1500000	usd
CY2024Q1	qomo	Conversion Price Per Unit ConversionPricePerUnit	10
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of the common stock are entitled to one vote for each share
CY2021	qomo	Percentage Of Issued And Outstanding Shares PercentageOfIssuedAndOutstandingShares	0.20	pure
CY2022Q4	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	119250	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1662623	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1662623	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1662623	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1662623	shares
CY2024Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	837857	shares
CY2024Q1	qomo	Class Of Warrant Or Right Redemption Of Warrants Or Rights Threshold Trading Days ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays	30	days
CY2024Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	9440722	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	9299336	usd
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5273000	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5273000	shares
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties		usd
CY2024Q1	qomo	Proceeds From Cash Withdrawal From Trust Account To Pay Franchise Tax ProceedsFromCashWithdrawalFromTrustAccountToPayFranchiseTax		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	qomo	Extension Fees Paid By The Sponsor Through Due To Related Party ExtensionFeesPaidByTheSponsorThroughDueToRelatedParty		usd
CY2023Q1	qomo	Accrued Expenses Paid By The Sponsor Through Due To Related Party AccruedExpensesPaidByTheSponsorThroughDueToRelatedParty		usd
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001894210

Files In Submission

Name	View Source	Status
0001013762-24-001078-index-headers.html	Edgar Link	pending
0001013762-24-001078-index.html	Edgar Link	pending
0001013762-24-001078.txt	Edgar Link	pending
0001013762-24-001078-xbrl.zip	Edgar Link	pending
ea0209524-10q_qomolang.htm	Edgar Link	pending
ea020952401ex10-10_qomo.htm	Edgar Link	pending
ea020952401ex10-2_qomo.htm	Edgar Link	pending
ea0209524-10q_qomolang_htm.xml	Edgar Link	completed
ea020952401ex10-3_qomo.htm	Edgar Link	pending
ea020952401ex10-4_qomo.htm	Edgar Link	pending
ea020952401ex10-5_qomo.htm	Edgar Link	pending
ea020952401ex10-6_qomo.htm	Edgar Link	pending
ea020952401ex10-7_qomo.htm	Edgar Link	pending
ea020952401ex10-8_qomo.htm	Edgar Link	pending
ea020952401ex10-9_qomo.htm	Edgar Link	pending
ea020952401ex31-1_qomo.htm	Edgar Link	pending
ea020952401ex31-2_qomo.htm	Edgar Link	pending
ea020952401ex32-1_qomo.htm	Edgar Link	pending
ea020952401ex32-2_qomo.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qomo-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
qomo-20240331_cal.xml	Edgar Link	unprocessable
qomo-20240331_def.xml	Edgar Link	unprocessable
qomo-20240331_lab.xml	Edgar Link	unprocessable
qomo-20240331_pre.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Qomolangma Acquisition Corp.

2024 Q1 Form 10-Q Financial Statement

#000101376224001078 Filed on July 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission